Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
1,151-1,200 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__86_A4,14 | Lung | Primary cancer | 1,475 | Stromal | 29.8% | 0.61 | 0.71 |
| NSCLC_38242124__IMC__86_A4,2 | Lung | Primary cancer | 3,098 | Stromal | 29.5% | 0.83 | 0.45 |
| NSCLC_38242124__IMC__86_A4,4 | Lung | Primary cancer | 2,095 | Tumor/Malignant | 36.2% | 0.93 | 0.20 |
| NSCLC_38242124__IMC__86_A4,5 | Lung | Primary cancer | 2,889 | Tumor/Malignant | 50.1% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__86_A4,7 | Lung | Primary cancer | 4,264 | Tumor/Malignant | 23.0% | 0.94 | 0.22 |
| NSCLC_38242124__IMC__86_A4,8 | Lung | Primary cancer | 2,515 | Tumor/Malignant | 35.6% | 0.94 | 0.17 |
| NSCLC_38242124__IMC__86_A4,9 | Lung | Primary cancer | 3,185 | Tumor/Malignant | 69.8% | 0.96 | 0.11 |
| NSCLC_38242124__IMC__86_A5,10 | Lung | Primary cancer | 2,294 | Tumor/Malignant | 51.2% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__86_A5,11 | Lung | Primary cancer | 3,978 | Stromal | 64.6% | 0.91 | 0.23 |
| NSCLC_38242124__IMC__86_A5,12 | Lung | Primary cancer | 2,767 | Tumor/Malignant | 51.6% | 0.95 | 0.21 |
| NSCLC_38242124__IMC__86_A5,14 | Lung | Primary cancer | 1,882 | Stromal | 25.1% | 0.78 | 0.55 |
| NSCLC_38242124__IMC__86_A5,3 | Lung | Primary cancer | 424 | Immune | 49.5% | 0.87 | 0.31 |
| NSCLC_38242124__IMC__86_A5,4 | Lung | Primary cancer | 3,268 | Tumor/Malignant | 50.6% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__86_A5,5 | Lung | Primary cancer | 3,568 | Tumor/Malignant | 38.1% | 0.93 | 0.19 |
| NSCLC_38242124__IMC__86_A5,6 | Lung | Primary cancer | 4,220 | Immune | 31.0% | 0.91 | 0.24 |
| NSCLC_38242124__IMC__86_A5,7 | Lung | Primary cancer | 2,727 | Tumor/Malignant | 56.6% | 0.97 | 0.09 |
| NSCLC_38242124__IMC__86_A5,8 | Lung | Primary cancer | 3,225 | Tumor/Malignant | 33.5% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__86_A5,9 | Lung | Primary cancer | 1,899 | Tumor/Malignant | 50.8% | 0.93 | 0.22 |
| NSCLC_38242124__IMC__86_A6,1 | Lung | Primary cancer | 3,030 | Tumor/Malignant | 40.4% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_A6,10 | Lung | Primary cancer | 348 | Tumor/Malignant | 68.1% | 0.97 | 0.06 |
| NSCLC_38242124__IMC__86_A6,11 | Lung | Primary cancer | 859 | Stromal | 27.0% | 0.54 | 0.79 |
| NSCLC_38242124__IMC__86_A6,12 | Lung | Primary cancer | 2,618 | Tumor/Malignant | 27.2% | 0.92 | 0.29 |
| NSCLC_38242124__IMC__86_A6,13 | Lung | Primary cancer | 1,610 | Tumor/Malignant | 42.8% | 0.96 | 0.19 |
| NSCLC_38242124__IMC__86_A6,14 | Lung | Primary cancer | 2,761 | Tumor/Malignant | 54.4% | 0.90 | 0.30 |
| NSCLC_38242124__IMC__86_A6,3 | Lung | Primary cancer | 1,879 | Stromal | 26.3% | 0.68 | 0.75 |
| NSCLC_38242124__IMC__86_A6,4 | Lung | Primary cancer | 3,001 | Tumor/Malignant | 57.0% | 0.95 | 0.20 |
| NSCLC_38242124__IMC__86_A6,5 | Lung | Primary cancer | 4,206 | Immune | 28.8% | 0.89 | 0.34 |
| NSCLC_38242124__IMC__86_A6,6 | Lung | Primary cancer | 352 | Tumor/Malignant | 65.6% | 0.91 | 0.23 |
| NSCLC_38242124__IMC__86_A6,7 | Lung | Primary cancer | 2,666 | Immune | 32.0% | 0.32 | 0.96 |
| NSCLC_38242124__IMC__86_A6,8 | Lung | Primary cancer | 2,608 | Tumor/Malignant | 74.8% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__86_A6,9 | Lung | Primary cancer | 1,491 | Tumor/Malignant | 43.7% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__86_A7,1 | Lung | Primary cancer | 2,317 | Tumor/Malignant | 58.9% | 0.97 | 0.08 |
| NSCLC_38242124__IMC__86_A7,10 | Lung | Primary cancer | 2,375 | Tumor/Malignant | 30.7% | 0.96 | 0.19 |
| NSCLC_38242124__IMC__86_A7,11 | Lung | Primary cancer | 2,116 | Stromal | 45.1% | 0.87 | 0.35 |
| NSCLC_38242124__IMC__86_A7,12 | Lung | Primary cancer | 540 | Other | 64.1% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__86_A7,13 | Lung | Primary cancer | 4,267 | Tumor/Malignant | 26.8% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__86_A7,2 | Lung | Primary cancer | 2,945 | Tumor/Malignant | 48.8% | 0.88 | 0.36 |
| NSCLC_38242124__IMC__86_A7,4 | Lung | Primary cancer | 4,008 | Tumor/Malignant | 28.8% | 0.54 | 0.85 |
| NSCLC_38242124__IMC__86_A7,5 | Lung | Primary cancer | 3,313 | Tumor/Malignant | 80.1% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__86_A7,7 | Lung | Primary cancer | 1,967 | Tumor/Malignant | 52.6% | 0.91 | 0.28 |
| NSCLC_38242124__IMC__86_A7,8 | Lung | Primary cancer | 2,968 | Stromal | 49.4% | 0.96 | 0.14 |
| NSCLC_38242124__IMC__86_A7,9 | Lung | Primary cancer | 2,881 | Other | 31.9% | 0.40 | 0.98 |
| NSCLC_38242124__IMC__86_A8,1 | Lung | Primary cancer | 2,834 | Tumor/Malignant | 31.0% | 0.77 | 0.62 |
| NSCLC_38242124__IMC__86_A8,10 | Lung | Primary cancer | 3,285 | Immune | 35.6% | 0.50 | 0.88 |
| NSCLC_38242124__IMC__86_A8,11 | Lung | Primary cancer | 2,883 | Stromal | 31.2% | 0.56 | 0.80 |
| NSCLC_38242124__IMC__86_A8,12 | Lung | Primary cancer | 3,110 | Tumor/Malignant | 61.4% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__86_A8,14 | Lung | Primary cancer | 2,257 | Tumor/Malignant | 38.7% | 0.89 | 0.35 |
| NSCLC_38242124__IMC__86_A8,2 | Lung | Primary cancer | 868 | Tumor/Malignant | 47.0% | 0.93 | 0.24 |
| NSCLC_38242124__IMC__86_A8,3 | Lung | Primary cancer | 3,118 | Tumor/Malignant | 50.5% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__86_A8,4 | Lung | Primary cancer | 3,640 | Tumor/Malignant | 29.1% | 0.93 | 0.24 |